- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05392699
ABOD2011 hos patienter med avancerede solide tumorer udviklet sig efter standard systemisk terapi
En åben-blind dosiseskaleringsundersøgelse for at vurdere sikkerheden, tolerabiliteten og den foreløbige effektivitet af ABOD2011 hos patienter med avancerede solide tumorer, der er udviklet efter standard systemisk terapi
Based on the activation and regulation of immune system by cytokines, mRNA encoding cytokines has become one of the important directions of mRNA tumor drug development. This product (ABOD2011) is a new generation mRNA product for intratumoral injection.
The primary objective of this study is to assess the safety and tolerability, of ABOD2011 in patients with advanced solid tumors that progressed after standard systemic therapy.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Beijing, Kina
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- 18 years and older.
- Understand and voluntarily sign the informed consent form (ICF).
- Histopathologically confirmed recurrent or metastatic solid tumors.
- Failure of prior systemic standard of care, or intolerance to severe toxicity, or lack of standard of care.
- Presence of at least one measurable lesion as assessed by RECIST Version 1.1.
- At least one superficial or deep lesion for intratumoral administration and biopsy.
- Sufficient organ functions.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
- Weight > 30 kg.
- Expected survival longer than 12 weeks.
- Evidence of menopause in female patients, or for women of childbearing potential: negative for urine or blood pregnancy.
Exclusion Criteria:
- Any systemic anti-tumor therapy, within 28 days prior to the first dose.
- Radiotherapy within 14 days prior to first dose.
- Use of immunosuppressants.
- Major surgery within 28 days.
- Inadequately controlled diseases.
- Active autoimmune and inflammatory diseases.
- Clinically symptomatic central nervous system tumors or metastases.
- Toxicity of prior anti-tumor therapy is still NCI-CTCAE ≥ 2.
- Other malignancies within the previous 5 years with the exception of cured basal cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the breast, and carcinoma in situ of the cervix.
- Active infections.
- Other conditions that may increase the risk associated with the study drug, or affect the study compliance, etc., which, in the opinion of the investigator, are not suitable for participation in the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Human single chain IL-12 mRNA-single dose
Human single chain IL-12 mRNA-single dose |
human single chain IL-12 mRNA administered as specified in the treatment arm with injection once only |
|
Eksperimentel: Human single chain IL-12 mRNA-multiple dose
Human single chain IL-12 mRNA-multiple dose |
human single chain IL-12 mRNA administered as specified in the treatment arm with injection once per week for 3 weeks |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants Experiencing dose-limiting toxicities (DLTs)
Tidsramme: From first dose to Day 28
|
Number of Participants Experiencing dose-limiting toxicities (DLTs) |
From first dose to Day 28
|
|
Number of Participants Experiencing Adverse Events (AEs)
Tidsramme: From signed ICF until the date of last visit or start new antitumor therapy, whichever comes first, assessed up to 36 months
|
Number of Participants Experiencing Adverse Events (AEs) |
From signed ICF until the date of last visit or start new antitumor therapy, whichever comes first, assessed up to 36 months
|
|
Number of Participants Experiencing Severe Adverse Events (SAEs)
Tidsramme: From signed ICF until the date of last visit or start new antitumor therapy, whichever came first, assessed up to 24 months
|
Number of Participants Experiencing Severe Adverse Events (SAEs) |
From signed ICF until the date of last visit or start new antitumor therapy, whichever came first, assessed up to 24 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Response Rate (ORR)
Tidsramme: Up to 36 months
|
Overall Response Rate (ORR) |
Up to 36 months
|
|
Disease Control Rate(DCR)
Tidsramme: Up to 36 months
|
Disease Control Rate(DCR) |
Up to 36 months
|
|
Duration of Response (DOR)
Tidsramme: Up to 36 months
|
Duration of Response (DOR) |
Up to 36 months
|
|
Progression-Free Survival (PFS)
Tidsramme: Up to 36 months
|
Progression-Free Survival (PFS) |
Up to 36 months
|
|
Overall Survival
Tidsramme: Up to 36 months
|
Overall Survival |
Up to 36 months
|
|
Maximum observed concentration (Cmax) of ABOD2011
Tidsramme: From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
Maximum observed concentration (Cmax) of ABOD2011 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
|
Area under the concentration-time curve (AUC) of ABOD2011
Tidsramme: From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
Area under the concentration-time curve (AUC) of ABOD2011 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
|
Maximum observed concentration (Cmax) of IL-12
Tidsramme: From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
Maximum observed concentration (Cmax) of IL-12 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product
|
|
Area under the concentration-time curve (AUC) of IL-12
Tidsramme: From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
Area under the concentration-time curve (AUC) of IL-12 |
From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
|
Plasma concentration of IFN gamma
Tidsramme: From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
Plasma concentration of IFN gamma |
From first dose of ABOD2011 through to 28 days after last dose of investigational product.
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Ning Li, Doctor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- ABOD2011-001
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .